Posted by Michael Wonder on 13 Sep 2024
Proposal to fund medicines for lung cancer, breast cancer, and respiratory conditions
13 September 2024 - PHARMAC is seeking feedback on a proposal to fund four new medicines for cancer and respiratory conditions.
Public consultation opened today on proposed funding for:
- Osimertinib mesylate (Tagrisso) for certain patients with advanced non-small-cell lung cancer as a first treatment option after diagnosis (first-line treatment), and for those who have received other treatments (second-line treatment).
- Trastuzumab deruxtecan (Enhertu) for patients with HER2 positive metastatic breast cancer
- Palivizumab (Synagis) for preventing RSV in infants and young children at high risk of infection
- Budesonide with eformoterol fumarate dihydrate and glycopyrronium bromide (Breztri Aerosphere) for patients with chronic obstructive pulmonary disease
